PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
7.01%
Growth of 7.01% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
8.23%
Cost growth of 8.23% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
2.37%
Growth of 2.37% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-4.34%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.92%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
2.35%
Operating expenses change of 2.35% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
7.13%
Total costs change of 7.13% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
3.45%
Interest expense change of 3.45% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
25.94%
D&A change of 25.94% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
22.81%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 0.71%. Joel Greenblatt would investigate advantages.
14.76%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 1.45%. Joel Greenblatt would investigate advantages.
2.53%
Income change of 2.53% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-4.19%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-26.75%
Other expenses reduction while Medical - Pharmaceuticals median is -5.60%. Seth Klarman would investigate advantages.
-2.63%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-9.01%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-2.33%
Tax expense reduction while Medical - Pharmaceuticals median is 5.00%. Seth Klarman would investigate advantages.
-2.89%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-9.25%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-2.89%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-2.89%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.